Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Ondansetron (Primary)
- Indications Irritable bowel syndrome
- Focus Proof of concept; Therapeutic Use
- Acronyms IBS-D
- Sponsors RedHill Biopharma
- 17 Jul 2017 Status changed from active, no longer recruiting to completed, according to a RedHill Biopharma media release.
- 14 Jun 2017 According to a RedHill Biopharma media release, topline results from this trial are expected in September 2017.
- 24 Apr 2017 Status changed from recruiting to active, no longer recruiting, according to a RedHill Biopharma media release.